Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Fabry Disease Treatment Market
Fabry Disease Treatment Market Size
- Report ID: GMI4237
- Published Date: Sep 2022
- Report Format: PDF
Fabry Disease Treatment Market Size
Fabry Disease Treatment Market was valued at over USD 1.7 billion in 2021. Driven by the increasing burden of heart and other organ-related problems in late-onset Fabry disease patients, the industry is expected to depict a CAGR of over 8% from 2022 to 2030
The incidence rate of Fabry disease continues to rise worldwide. Chaperone and ERT (enzyme replacement therapy) are common therapeutic approaches designed to improve the clinical symptoms of patients with this genetic disease. The type 1 classic and late-onset Fabry disease symptoms, which are three times to ten times more common than the classic type, are becoming prevalent, especially among men.
Based on recent research, Fabry disease is also emerging as the second most common genetic metabolic storage disease, often resulting in progressive organ damage or failure and premature death. Heart problems in patients with Fabry disease include the enlargement of heart muscles due to extra effort required to pump blood. This condition is common among patients with late-onset Fabry disease aged 40 years or above. The rapidly aging population is thus expected to accelerate Fabry disease diagnosis and treatment, stimulating industry statistics.
| Report Attribute | Details |
|---|---|
| Base Year: | 2021 |
| Fabry Disease Treatment Market Size in 2021: | USD 1,794.6 million |
| Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 8% |
| 2030 Value Projection: | USD 3,553.6 million |
| Historical Data for: | 2017 to 2021 |
| No. of Pages: | 109 |
| Tables, Charts & Figures: | 136 |
| Segments covered: | Treatment Type and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Fabry Disease Treatment Market Scope
